- Main
COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial
- Habtehyimer, Feben;
- Zhu, Xianming;
- Redd, Andrew D;
- Gebo, Kelly A;
- Abraham, Alison G;
- Patel, Eshan U;
- Laeyendecker, Oliver;
- Gniadek, Thomas J;
- Fernandez, Reinaldo E;
- Baker, Owen R;
- Ram, Malathi;
- Cachay, Edward R;
- Currier, Judith S;
- Fukuta, Yuriko;
- Gerber, Jonathan M;
- Heath, Sonya L;
- Meisenberg, Barry;
- Huaman, Moises A;
- Levine, Adam C;
- Shenoy, Aarthi;
- Anjan, Shweta;
- Blair, Janis E;
- Cruser, Daniel;
- Forthal, Donald N;
- Hammitt, Laura L;
- Kassaye, Seble;
- Mosnaim, Giselle S;
- Patel, Bela;
- Paxton, James H;
- Raval, Jay S;
- Sutcliffe, Catherine G;
- Abinante, Matthew;
- Oei, Kevin S;
- Cluzet, Valerie;
- Cordisco, Marie Elena;
- Greenblatt, Benjamin;
- Rausch, William;
- Shade, David;
- Gawad, Amy L;
- Klein, Sabra L;
- Pekosz, Andrew;
- Shoham, Shmuel;
- Casadevall, Arturo;
- Bloch, Evan M;
- Hanley, Daniel;
- Tobian, Aaron AR;
- Sullivan, David J
- Editor(s): Liu, Benjamin M
Published Web Location
https://doi.org/10.1128/spectrum.03286-23Abstract
IMPORTANCE: This study examined the role that cytokines may have played in the beneficial outcomes found when outpatient individuals infected with SARS-CoV-2 were transfused with COVID-19 convalescent plasma (CCP) early in their infection. We found that the pro-inflammatory cytokine IL-6 decreased significantly faster in patients treated early with CCP. Participants with COVID-19 treated with CCP later in the infection did not have the same effect. This decrease in IL-6 levels after early CCP treatment suggests a possible role of inflammation in COVID-19 progression. The evidence of IL-6 involvement brings insight into the possible mechanisms involved in CCP treatment mitigating SARS-CoV-2 severity.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.